These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25707966)

  • 1. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
    Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
    AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.
    Lee JW; Salimi-Moosavi H
    Bioanalysis; 2012 Oct; 4(20):2513-23. PubMed ID: 23157359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK-PD modeling of protein drugs: implications in assay development.
    Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
    Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.
    Myzithras M; Lin S; Radden L; Hess Kenny C; Cai Z; MacDonald A; Binetti R; Marlow M; Fracasso P; Gibson G; Bartlett C; Hawkins J; Hansel S
    MAbs; 2022; 14(1):2104153. PubMed ID: 35916739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.
    Wang YM; Jawa V; Ma M
    Bioanalysis; 2014 Jan; 6(1):79-87. PubMed ID: 24341496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality.
    Mould DR; Frame B
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):91S-100S. PubMed ID: 20881222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model.
    Li X; Jusko WJ; Cao Y
    J Pharmacol Exp Ther; 2018 Oct; 367(1):1-8. PubMed ID: 30002096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Waltenberger H; Hansbauer A; Koehler A; Heinrich J
    J Pharm Biomed Anal; 2015 Jan; 102():459-67. PubMed ID: 25459946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.
    Neubert H; Fountain S; King L; Clark T; Weng Y; O'Hara DM; Li W; Leung S; Ray C; Palandra J; Ocaña MF; Chen J; Ji C; Wang M; Long K; Gorovits B; Fluhler E
    Bioanalysis; 2012 Nov; 4(21):2589-604. PubMed ID: 23173794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents.
    Visentin M; Biason P; Toffoli G
    Pharmacol Ther; 2010 Oct; 128(1):82-90. PubMed ID: 20542058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development.
    Spilker ME; Singh P; Vicini P
    Cytometry B Clin Cytom; 2016 Mar; 90(2):230-6. PubMed ID: 26296748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.